galantamine has been researched along with Mental Disorders in 17 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (5.88) | 18.2507 |
| 2000's | 6 (35.29) | 29.6817 |
| 2010's | 9 (52.94) | 24.3611 |
| 2020's | 1 (5.88) | 2.80 |
| Authors | Studies |
|---|---|
| Metz, CN; Pavlov, VA | 1 |
| Koola, MM | 1 |
| Cumbo, E; Ligori, LD | 1 |
| Matsuda, T | 1 |
| Morgan, S; Rodda, J; Walker, Z | 1 |
| Freedman, M; Kaye, ED; Petrovic-Poljak, A; Verhoeff, NP | 1 |
| Ago, Y; Koda, K; Matsuda, T; Takuma, K | 1 |
| Adam, MP; Cubells, JF; Deoreo, EH; Garber, K; Garlow, SJ; Harvey, PD; Martin, CL | 1 |
| Adami, M; Delgado, A; Gaudig, M; Guzman, C; Jedenius, E; Kavanagh, S; Schäuble, B; Van Baelen, B | 1 |
| Ago, Y; Fukada, A; Kita, Y; Koda, K; Matsuda, T; Ota, Y; Takuma, K | 1 |
| Al Owesie, RM; Morton, CS | 1 |
| Giannakopoulos, P; Monsch, AU | 1 |
| Binder, C; Herrmann, N; Rabheru, K; Wang, J | 1 |
| Cummings, JL | 1 |
| Beier, MT | 1 |
| Campanozzi, MD; Casali, E; Martini, E; Neri, M; Neviani, F | 1 |
| Bahro, M; Berger, M; Gann, H; Hohagen, F; Lis, S; Riemann, D; Stadmüller, G | 1 |
8 review(s) available for galantamine and Mental Disorders
| Article | Year |
|---|---|
Treating disorders across the lifespan by modulating cholinergic signaling with galantamine.
Topics: Acetylcholinesterase; Animals; Anti-Inflammatory Agents; Brain; Cholinergic Agents; Cholinesterase Inhibitors; Galantamine; Humans; Longevity; Mental Disorders; Neurodegenerative Diseases | 2021 |
Galantamine-Memantine Combination for Cognitive Impairments Due to Electroconvulsive Therapy, Traumatic Brain Injury, and Neurologic and Psychiatric Disorders: Kynurenic Acid and Mismatch Negativity Target Engagement.
Topics: Animals; Cognitive Dysfunction; Drug Therapy, Combination; Electroconvulsive Therapy; Galantamine; Humans; Kynurenic Acid; Memantine; Mental Disorders; Nervous System Diseases; Nootropic Agents | 2018 |
Psychopharmacological Studies in Mice.
Topics: Alzheimer Disease; Animals; Cholinesterase Inhibitors; Disease Models, Animal; Donepezil; Dopamine; Drug Discovery; Environment; Female; Galantamine; Indans; Male; Mental Disorders; Mice; Molecular Targeted Therapy; Motivation; Piperidines; Psychopharmacology; Rats; Receptor, Serotonin, 5-HT1A; Receptor, Serotonin, 5-HT1D; Receptors, Dopamine D2; Research; Rivastigmine | 2016 |
Are cholinesterase inhibitors effective in the management of the behavioral and psychological symptoms of dementia in Alzheimer's disease? A systematic review of randomized, placebo-controlled trials of donepezil, rivastigmine and galantamine.
Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Evidence-Based Medicine; Galantamine; Humans; Indans; Mental Disorders; Nootropic Agents; Phenylcarbamates; Piperidines; Randomized Controlled Trials as Topic; Rivastigmine; Treatment Outcome | 2009 |
Frontotemporal dementia and pharmacologic interventions.
Topics: Antidepressive Agents; Brain; Choline O-Acetyltransferase; Cholinesterase Inhibitors; Corpus Striatum; Dopamine; Frontotemporal Dementia; Galantamine; Humans; Mental Disorders; Neuroprotective Agents; Phenylcarbamates; Receptors, Serotonin; Rivastigmine; Selegiline | 2010 |
Pharmacological aspects of the acetylcholinesterase inhibitor galantamine.
Topics: Allosteric Regulation; Animals; Cholinesterase Inhibitors; Galantamine; Humans; Mental Disorders; Muscarinic Agonists; Nicotinic Agonists; Psychotropic Drugs | 2011 |
Galantamine and behavior in Alzheimer disease: analysis of four trials.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Caregivers; Double-Blind Method; Female; Galantamine; Humans; Male; Mental Disorders; Randomized Controlled Trials as Topic | 2011 |
Treatment strategies for the behavioral symptoms of Alzheimer's disease: focus on early pharmacologic intervention.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Galantamine; Humans; Indans; Memantine; Mental Disorders; Piperidines; Time Factors | 2007 |
3 trial(s) available for galantamine and Mental Disorders
| Article | Year |
|---|---|
Differential effects of current specific treatments on behavioral and psychological symptoms in patients with Alzheimer's disease: a 12-month, randomized, open-label trial.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Behavioral Symptoms; Cholinesterase Inhibitors; Dementia; Donepezil; Excitatory Amino Acid Antagonists; Female; Galantamine; Humans; Indans; Longitudinal Studies; Male; Memantine; Mental Disorders; Phenylcarbamates; Piperidines; Psychiatric Status Rating Scales; Rivastigmine | 2014 |
Galantamine treatment of problematic behavior in Alzheimer disease: post-hoc analysis of pooled data from three large trials.
Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Delusions; Double-Blind Method; Female; Galantamine; Humans; Male; Mental Disorders; Psychomotor Agitation; Treatment Outcome | 2005 |
Cholinergic neurotransmission, REM sleep and depression.
Topics: Adolescent; Adult; Aged; Alzheimer Disease; Brain Stem; Cholinergic Agonists; Cholinergic Fibers; Depressive Disorder; Dose-Response Relationship, Drug; Double-Blind Method; Female; Galantamine; Humans; Male; Mental Disorders; Middle Aged; Parasympathomimetics; Physostigmine; Polysomnography; Reaction Time; Receptors, Muscarinic; Sleep Stages; Sleep Wake Disorders; Sleep, REM; Succinimides; Synaptic Transmission; Tacrine | 1994 |
6 other study(ies) available for galantamine and Mental Disorders
| Article | Year |
|---|---|
Pharmaco-genetically guided treatment of recurrent rage outbursts in an adult male with 15q13.3 deletion syndrome.
Topics: Adult; Cholinesterase Inhibitors; Chromosome Deletion; Chromosomes, Human, Pair 15; Epilepsy; Female; Galantamine; Humans; Male; Mental Disorders; Pharmacogenetics; Phenotype; Rage; Schizophrenia; Syndrome | 2011 |
Donepezil, but not galantamine, blocks muscarinic receptor-mediated in vitro and in vivo responses.
Topics: Animals; Animals, Outbred Strains; Cell Line, Tumor; Cerebral Cortex; Cholinesterase Inhibitors; Disease Models, Animal; Donepezil; Galantamine; Humans; Indans; Male; Mental Disorders; Mice; Muscarinic Antagonists; Piperidines; Receptors, Muscarinic | 2011 |
Psychopharmacologic intervention after hemorrhagic basal ganglia damage.
Topics: Adult; Basal Ganglia Hemorrhage; Cognition Disorders; Galantamine; Glasgow Coma Scale; Humans; Male; Mental Disorders; Methylphenidate; Neuropsychological Tests; Nootropic Agents; Tomography Scanners, X-Ray Computed | 2012 |
Effects of galantamine on behavioural and psychological disturbances and caregiver burden in patients with Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Caregivers; Female; Galantamine; Humans; Male; Mental Disorders; Middle Aged; Nootropic Agents; Switzerland | 2004 |
Behavioral and neuropsychiatric outcomes in Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Brain; Diagnostic and Statistical Manual of Mental Disorders; Galantamine; Humans; Mental Disorders; Phenylcarbamates; Prevalence; Rivastigmine | 2005 |
Evaluation of the slopes of cognitive impairment and disability in Alzheimer's disease (AD) patients treated with acetylcholinesterase inhibitors (AChEl).
Topics: Activities of Daily Living; Aged; Alzheimer Disease; Cholinesterase Inhibitors; Cognition Disorders; Diagnostic and Statistical Manual of Mental Disorders; Disability Evaluation; Donepezil; Female; Follow-Up Studies; Galantamine; Humans; Indans; Male; Mental Disorders; Neuropsychological Tests; Phenylcarbamates; Piperidines; Rivastigmine; Severity of Illness Index | 2007 |